Overview
Direct Coomb’s test is an immunohematological assay used to detect antibodies or complement proteins already bound to the surface of red blood cells in vivo. It identifies immune-mediated red cell destruction by demonstrating antigen–antibody reactions using anti-human globulin reagent. The test plays a key role in diagnosing hemolytic conditions and assessing immune causes of anemia. It is routinely used in transfusion medicine, neonatal care, and evaluation of hemolytic disorders.
Symptoms
Direct Coomb’s test is performed in patients presenting with signs of hemolysis. Common symptoms include anemia, jaundice, pallor, fatigue, dark-colored urine, and elevated bilirubin levels. Newborns may present with jaundice or anemia suggestive of hemolytic disease of the newborn. Patients with transfusion reactions may develop fever, hemoglobinuria, or a sudden drop in hemoglobin levels.
Causes
A positive Direct Coomb’s test indicates immune-mediated coating of red blood cells with IgG antibodies or complement. This occurs in autoimmune hemolytic anemia, where autoantibodies target red cells. It is also seen in hemolytic disease of the newborn due to ABO or Rh incompatibility, drug-induced hemolytic anemia, and hemolytic transfusion reactions. Certain infections, autoimmune disorders, and medications can trigger antibody formation against red blood cells.
Risk Factors
Risk factors for a positive Direct Coomb’s test include autoimmune diseases, prior blood transfusions, pregnancy with blood group incompatibility, and exposure to drugs known to induce immune hemolysis. Newborns born to sensitized mothers and patients with chronic hemolytic anemia are at increased risk. Underlying malignancies and immune dysregulation can also contribute.
Prevention
While immune-mediated hemolysis cannot always be prevented, early identification using the Direct Coombs test helps prevent severe complications. Proper blood grouping, cross-matching, and antenatal screening reduce the risk of transfusion reactions and hemolytic disease of the newborn. Avoidance of offending drugs and timely management of autoimmune conditions reduces recurrence. Accurate testing, careful sample handling, and clinical correlation ensure effective diagnosis and patient management.
